Inhalation Sciences Q1’22: Eventful Start to 2022
Research Note
2022-05-23
10:30
Redeye comments on ISAB’s Q1’22 report. The company has seen a continued high interest for its IRS business during the first quarter and with a pending FDA approval for its white paper proposal submitted in January, the company has an interesting period ahead.
EN
GM
Erik Nordström
Gustaf Meyer
Disclosures and disclaimers